2CBCB-NBOMe

2CBCB-NBOMe

Systematic (IUPAC) name
N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine
Clinical data
Legal status	Uncontrolled
Identifiers
CAS Number	1354634-09-5 N
ChemSpider	26234935 Y
Chemical data
Formula	C19H22BrNO3
Molecular mass	392.286 g/mol
SMILES COc1ccccc1CNCC3c2c(C3)c(OC)c(Br)cc2OC
InChI InChI=1S/C19H22BrNO3/c1-22-16-7-5-4-6-12(16)10-21-11-13-8-14-18(13)17(23-2)9-15(20)19(14)24-3/h4-7,9,13,21H,8,10-11H2,1-3H3/t13-/m0/s1 Y Key:CLSBQRBXTFTLEX-ZDUSSCGKSA-N Y
NY (what is this?)  (verify)

2CBCB-NBOMe (NBOMe-TCB-2) is a compound indirectly derived from the phenethylamine series of hallucinogens, which was discovered in 2007 at Purdue University as part of the ongoing research program of the team led by David Nichols focusing on the mapping of the specific amino acid residues responsible for ligand binding to the 5HT_2A receptor. 2CBCB-NBOMe acts as a potent and selective agonist for the 5-HT_2A and 5-HT_2C receptors, with a Ki of 0.27nM at the human 5-HT_2A receptor, a similar potency to other agonists such as TCB-2, NBOMe-2C-I and Bromo-DragonFLY.

Legality

2CBCB-NBOMe is a controlled substance in Vermont as of January 2016.

See also

• 2CBFly-NBOMe (NBOMe-2CB-Fly)
• 2C-C-NBOMe (NBOMe-2CC)
• 25B-NBOMe (NBOMe-2CB)
• 25I-NBMD (NBMD-2CI)
• 25B-NBOH
• 25I-NBOH (NBOH-2CI)
• 25I-NBOMe (NBOMe-2CI)
• 2C-TFM-NBOMe (NBOMe-2C-TFM)
• 25I-NBF (NBF-2CI)